TY - JOUR
T1 - Three weeks of time-restricted eating improves glucose homeostasis in adults with type 2 diabetes but does not improve insulin sensitivity: a randomised crossover trial
AU - Andriessen, C.
AU - Fealy, C.E.
AU - Veelen, A.
AU - van Beek, S.M.M.
AU - Roumans, K.H.M.
AU - Connell, N.J.
AU - Mevenkamp, J.
AU - Moonen-Kornips, E.
AU - Havekes, B.
AU - Schrauwen-Hinderling, V.B.
AU - Hoeks, J.
AU - Schrauwen, P.
N1 - Funding Information:
Some of the data were presented as an abstract at the ZoomForward2022: European Congress on Obesity meeting in 2022, at the Dutch Diabetes Research Meeting in 2021 and at the 57thEASD Annual Meeting in 2021. The authors thank all the enthusiastic volunteers in this study for their participation. The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. CA, CEF, JH and PS designed the experiments. CA, CEF, AV, KHMR, SMMvB, EM-K, NJC and BH performed the measurements. CA, AV, VBS-H, JM, JH and PS were involved in data analysis. CA, JH and PS drafted the manuscript. All authors reviewed and approved the final version of the manuscript. PS is the guarantor of this work and, as such, has full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/10
Y1 - 2022/10
N2 - Aims/hypothesis Time-restricted eating (TRE) is suggested to improve metabolic health by limiting food intake to a defined time window, thereby prolonging the overnight fast. This prolonged fast is expected to lead to a more pronounced depletion of hepatic glycogen stores overnight and might improve insulin sensitivity due to an increased need to replenish nutrient storage. Previous studies showed beneficial metabolic effects of 6-8 h TRE regimens in healthy, overweight adults under controlled conditions. However, the effects of TRE on glucose homeostasis in individuals with type 2 diabetes are unclear. Here, we extensively investigated the effects of TRE on hepatic glycogen levels and insulin sensitivity in individuals with type 2 diabetes.Methods Fourteen adults with type 2 diabetes (BMI 30.5 +/- 4.2 kg/m(2), HbA(1c) 46.1 +/- 7.2 mmol/mol [6.4 +/- 0.7%]) participated in a 3 week TRE (daily food intake within 10 h) vs control (spreading food intake over >= 14 h) regimen in a randomised, crossover trial design. The study was performed at Maastricht University, the Netherlands. Eligibility criteria included diagnosis of type 2 diabetes, intermediate chronotype and absence of medical conditions that could interfere with the study execution and/or outcome. Randomisation was performed by a study-independent investigator, ensuring that an equal amount of participants started with TRE and CON. Due to the nature of the study, neither volunteers nor investigators were blinded to the study interventions. The quality of the data was checked without knowledge on intervention allocation. Hepatic glycogen levels were assessed with C-13-MRS and insulin sensitivity was assessed using a hyperinsulinaemic-euglycaemic two-step clamp. Furthermore, glucose homeostasis was assessed with 24 h continuous glucose monitoring devices. Secondary outcomes included 24 h energy expenditure and substrate oxidation, hepatic lipid content and skeletal muscle mitochondrial capacity.Results Results are depicted as mean +/- SEM. Hepatic glycogen content was similar between TRE and control condition (0.15 +/- 0.01 vs 0.15 +/- 0.01 AU, p=0.88). Mvalue was not significantly affected by TRE (19.6 +/- 1.8 vs 17.7 +/- 1.8 mu mol kg(-1) min(-1) in TRE vs control, respectively, p=0.10). Hepatic and peripheral insulin sensitivity also remained unaffected by TRE (p=0.67 and p=0.25, respectively). Yet, insulin-induced non-oxidative glucose disposal was increased with TRE (non-oxidative glucose disposal 4.3 +/- 1.1 vs 1.5 +/- 1.7 mu mol kg(-1) min(-1), p=0.04). TRE increased the time spent in the normoglycaemic range (15.1 +/- 0.8 vs 12.2 +/- 1.1 h per day, p=0.01), and decreased fasting glucose (7.6 +/- 0.4 vs 8.6 +/- 0.4 mmol/l, p= 0.03) and 24 h glucose levels (6.8 +/- 0.2 vs 7.6 +/- 0.3 mmol/l, p<0.01). Energy expenditure over 24 h was unaffected; nevertheless, TRE decreased 24 h glucose oxidation (260.2 +/- 7.6 vs 277.8 +/- 10.7 g/day, p=0.04). No adverse events were reported that were related to the interventions.Conclusions/interpretation We show that a 10 h TRE regimen is a feasible, safe and effective means to improve 24 h glucose homeostasis in free-living adults with type 2 diabetes. However, these changes were not accompanied by changes in insulin sensitivity or hepatic glycogen.
AB - Aims/hypothesis Time-restricted eating (TRE) is suggested to improve metabolic health by limiting food intake to a defined time window, thereby prolonging the overnight fast. This prolonged fast is expected to lead to a more pronounced depletion of hepatic glycogen stores overnight and might improve insulin sensitivity due to an increased need to replenish nutrient storage. Previous studies showed beneficial metabolic effects of 6-8 h TRE regimens in healthy, overweight adults under controlled conditions. However, the effects of TRE on glucose homeostasis in individuals with type 2 diabetes are unclear. Here, we extensively investigated the effects of TRE on hepatic glycogen levels and insulin sensitivity in individuals with type 2 diabetes.Methods Fourteen adults with type 2 diabetes (BMI 30.5 +/- 4.2 kg/m(2), HbA(1c) 46.1 +/- 7.2 mmol/mol [6.4 +/- 0.7%]) participated in a 3 week TRE (daily food intake within 10 h) vs control (spreading food intake over >= 14 h) regimen in a randomised, crossover trial design. The study was performed at Maastricht University, the Netherlands. Eligibility criteria included diagnosis of type 2 diabetes, intermediate chronotype and absence of medical conditions that could interfere with the study execution and/or outcome. Randomisation was performed by a study-independent investigator, ensuring that an equal amount of participants started with TRE and CON. Due to the nature of the study, neither volunteers nor investigators were blinded to the study interventions. The quality of the data was checked without knowledge on intervention allocation. Hepatic glycogen levels were assessed with C-13-MRS and insulin sensitivity was assessed using a hyperinsulinaemic-euglycaemic two-step clamp. Furthermore, glucose homeostasis was assessed with 24 h continuous glucose monitoring devices. Secondary outcomes included 24 h energy expenditure and substrate oxidation, hepatic lipid content and skeletal muscle mitochondrial capacity.Results Results are depicted as mean +/- SEM. Hepatic glycogen content was similar between TRE and control condition (0.15 +/- 0.01 vs 0.15 +/- 0.01 AU, p=0.88). Mvalue was not significantly affected by TRE (19.6 +/- 1.8 vs 17.7 +/- 1.8 mu mol kg(-1) min(-1) in TRE vs control, respectively, p=0.10). Hepatic and peripheral insulin sensitivity also remained unaffected by TRE (p=0.67 and p=0.25, respectively). Yet, insulin-induced non-oxidative glucose disposal was increased with TRE (non-oxidative glucose disposal 4.3 +/- 1.1 vs 1.5 +/- 1.7 mu mol kg(-1) min(-1), p=0.04). TRE increased the time spent in the normoglycaemic range (15.1 +/- 0.8 vs 12.2 +/- 1.1 h per day, p=0.01), and decreased fasting glucose (7.6 +/- 0.4 vs 8.6 +/- 0.4 mmol/l, p= 0.03) and 24 h glucose levels (6.8 +/- 0.2 vs 7.6 +/- 0.3 mmol/l, p<0.01). Energy expenditure over 24 h was unaffected; nevertheless, TRE decreased 24 h glucose oxidation (260.2 +/- 7.6 vs 277.8 +/- 10.7 g/day, p=0.04). No adverse events were reported that were related to the interventions.Conclusions/interpretation We show that a 10 h TRE regimen is a feasible, safe and effective means to improve 24 h glucose homeostasis in free-living adults with type 2 diabetes. However, these changes were not accompanied by changes in insulin sensitivity or hepatic glycogen.
KW - Circadian rhythm
KW - Glucose homeostasis
KW - Hepatic fat
KW - Hepatic glycogen
KW - Insulin sensitivity
KW - Intermittent fasting
KW - Lifestyle intervention
KW - Mitochondrial oxidative capacity
KW - TRE
KW - Type 2 diabetes
KW - SKELETAL-MUSCLE
KW - DIURNAL-VARIATION
KW - LIPID-CONTENT
KW - TOLERANCE
KW - WEIGHT
KW - HEALTH
KW - RESISTANCE
KW - MELLITUS
KW - RISK
U2 - 10.1007/s00125-022-05752-z
DO - 10.1007/s00125-022-05752-z
M3 - Article
C2 - 35871650
SN - 0012-186X
VL - 65
SP - 1710
EP - 1720
JO - Diabetologia
JF - Diabetologia
IS - 10
M1 - s00125-022-05752-z
ER -